Study Overview
Comparison: Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in HR+/HER2- Advanced Breast Cancer.
Key Outcome: Analysis of Health-Related Quality of Life (HRQOL) from the MONALEESA-3 Phase III trial.
Study Design & Arms
Randomized, double-blind, placebo-controlled Phase III trial structure.
Hazard Ratios: Time to Deterioration (TTD)
Forest plot showing Hazard Ratios (HR) for definitive 10% deterioration. HR < 1 favors Ribociclib.
Baseline Scores (Mean ± SD)
Comparison of baseline Global Health Status (GHS) and Pain scores between groups.
Median Time to Deterioration (Months)
Comparison of median TTD across key metrics. "Not estimable" indicates median was not reached.
Metric Details: Dot Plot
Visualizing the spread of TTD values across all measured domains.
Study Timeline & Follow-up
Key temporal milestones of the MONALEESA-3 analysis.
Appendix: Raw Data & Provenance
| Metric | Group | Value | Source |
|---|